Avalon GloboCare Appoints Dr. Bo Chen as Vice President of Mergers & Acquisitions to Accelerate Growth
FREEHOLD, NJ -- (Marketwired) -- 01/16/18 -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has appointed Dr. Bo Chen as Vice President, Business Development to lead mergers & acquisitions activity. Dr. Chen will focus on executing Avalon's acquisition strategy by helping identify companies with a strategic fit within the cell therapeutics, cell diagnostics and rehabilitation sectors.
Dr. Bo Chen was one of the original founders of the Ludaopei Hospital Group in China, and has served as the global business development director for the past 5 years. The Ludaopei Hospital Group is one of the fastest growing private medical companies in China presently, consisting of multiple hospitals and research centers specialized in leukemia and cell therapeutics. Prior to joining the Ludaopei Hospital Group Dr. Chen had multiple leadership positions in healthcare and biotechnology industries. Dr. Chen holds a Ph.D. degree in engineering science from Virginia Tech.
Dr. David Jin, President and CEO of Avalon GloboCare, stated, "We are pleased to welcome Dr. Bo Chen to the senior management team. Dr. Chen has substantial knowledge and experience guiding global M&A activities within the healthcare sector. In addition to organic growth, our plan is to acquire established companies, with revenue growth and defensible intellectual property within our target verticals, where we can leverage our global reach, capabilities and resources. We are initially targeting companies within the cell therapeutics, diagnostics and rehabilitation sectors, as we believe each of these markets are poised for explosive growth and leverage our core capabilities and expertise."
Dr. Bo Chen, commented, "Avalon is at the forefront of the cell therapy market, developing disruptive technologies with immediate near-term clinical application. I am honored to be joining such an experienced and accomplished leadership team. There is a huge market opportunity in cell based therapies, especially in China, and we will be evaluating target companies in the U.S. and around the world where we can leverage our distinct relationships with some of the largest private medical groups in China."
ABOUT AVALON GLOBOCARE CORP.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, disruptive cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
Crescendo Communications, LLC
Tel: (212) 671-1020
Source: Avalon GloboCare Corp.
Released January 16, 2018